Expanded addressable market Dario has broadened its reach via Solera Health to include hypertension programs that expand the potential addressable population beyond high-risk diabetes, effectively increasing opportunities across large pre-hypertension to Stage 2 hypertension segments.

Enterprise channel leverage Existing channel partnerships with Solera, Amwell and other blue-chip partners grant access to over 116 million covered lives, with potential expansion to 175+ million, signaling robust enterprise sales avenues and large-scale contract opportunities.

Clinical and payor value ADA scientific sessions data underscore sustained engagement on Dario’s platform improves cardiometabolic outcomes and lowers care costs, supporting sales pitches to payers, employers and health plans about outcomes-based, value-driven contracts.

Growing revenue trajectory Q1 2026 results show sequential revenue growth and improved operating efficiency, with multiple new accounts and a sizable pipeline, indicating a favorable momentum for upsell and cross-sell across current enterprise customers.

Strategic product expansion Plans to broaden the digital health platform into care delivery and management suggest opportunities to bundle solutions for holistic health programs, enabling cross-sell into employer groups, health plans and enterprise buyers seeking integrated digital health services.